Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements review discovered that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://albertx382pxe6.dgbloggers.com/profile